<DOC>
	<DOCNO>NCT02301481</DOCNO>
	<brief_summary>This prospective , randomized phase II study design evaluate weather neoadjuvant chemoradiotherapy superior neoadjuvant chemotherapy follow surgery postoperative chemotherapy locally advance gastric adenocarcinoma .</brief_summary>
	<brief_title>A Randomized Phase II Trial Neoadjuvant Chemotherapy Compared With Chemoradiotherapy Gastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically proven locally advanced gastric adenocarcinoma patient stag cT34N0M0 anyTN+M0 No distant metastasis liver , lung , bone , central nervous system ( CNS ) , peritoneal transplantation No prior abdominal pelvic radiotherapy Karnofsky performance status ( KPS ) â‰¥ 70 , predictive life span le 6 month Patients must normal organ marrow function define : Leukocytes : great equal 3,000 G/L ; Platelets : great equal 100,000/mm3 .Hemoglobin : great equal 10g/L .Total bilirubin : within normal institutional limit ; AST/ALT : less equal 1.5 time upper limit ; Creatinine within normal upper limit Informed consent Any prior chemotherapy cancer treatment prior protocol Patients cancer history except cervical carcinoma situ nonmalignant melanoma skin cancer With distant metastasis liver , lung , bone , CNS , peritoneal transplantation History allergic reaction attribute similar chemical biologic complex S1 Xeloda Oxaliplatin Uncontrolled illness include , limited , active infection , symptomatic heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness History myocardial infarction within past 6 month history ventricular arrhythmia History prior radiation abdomen Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>